BMO Capital Markets Analysts Give Pfizer (PFE) a $43.00 Price Target

BMO Capital Markets set a $43.00 price target on Pfizer (NYSE:PFE) in a report released on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on PFE. Berenberg Bank set a $36.00 price objective on Pfizer and gave the company a neutral rating in a research report on Tuesday, January 30th. Societe Generale set a $40.00 price objective on Pfizer and gave the company a neutral rating in a research report on Wednesday, January 31st. UBS Group set a $42.00 price objective on Pfizer and gave the company a buy rating in a research report on Wednesday, January 31st. Leerink Swann raised their price objective on Pfizer from $35.00 to $38.00 and gave the company a market perform rating in a research report on Wednesday, January 31st. Finally, Morningstar set a $38.00 price objective on Pfizer and gave the company a neutral rating in a research report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. Pfizer has a consensus rating of Hold and an average price target of $39.45.

Shares of Pfizer (NYSE PFE) opened at $36.26 on Thursday. Pfizer has a 12-month low of $31.67 and a 12-month high of $39.43. The firm has a market capitalization of $216,135.23, a PE ratio of 10.33, a P/E/G ratio of 2.05 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the company earned $0.47 earnings per share. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. equities analysts expect that Pfizer will post 2.95 EPS for the current year.

Pfizer declared that its Board of Directors has initiated a stock repurchase program on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 38.75%.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Large investors have recently made changes to their positions in the company. HL Financial Services LLC raised its position in Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after acquiring an additional 35,744 shares in the last quarter. Hartford Financial Management Inc. raised its position in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 835 shares in the last quarter. Cadence Bank NA grew its holdings in Pfizer by 1.4% in the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 1,428 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in Pfizer by 437.9% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after purchasing an additional 629,361 shares during the period. Finally, Majedie Asset Management Ltd grew its holdings in Pfizer by 7.9% in the second quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after purchasing an additional 24,531 shares during the period. Hedge funds and other institutional investors own 70.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/18/bmo-capital-markets-analysts-give-pfizer-pfe-a-43-00-price-target-2.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply